#United States #Dallas #Chronic Pain #Neuros Medical #Altius System

A New Era in Pain Management for Amputees

In a remarkable advancement for the treatment of chronic post-amputation pain, Neuros Medical has successfully completed the first commercial implantation of the Altius® Direct Electrical Nerve Stimulation System in a patient in the United States. This milestone represents not only a significant breakthrough for lower limb amputees but also a vital step towards addressing a pressing medical challenge that many face after losing a limb.

The Altius System is notable for being the only FDA-approved device specifically designed to manage chronic post-amputation pain for individuals who have undergone lower limb amputations. Chronic post-amputation pain affects up to 80% of amputees, leaving them in search of lasting solutions beyond traditional treatments, which often rely heavily on opioids and gabapentinoids. The Altius System provides a novel alternative by delivering direct electrical nerve stimulation, which effectively blocks pain signals from reaching the brain.

Understanding the Altius System

The Altius System incorporates a patient-controlled mechanism that allows users to initiate treatment at their discretion through an on-demand system. With its unique design, which features a nerve cuff electrode that wraps around the affected nerve and an implantable pulse generator (IPG), patients can activate targeted 30-minute treatment sessions when they experience pain. This empowering approach enables individuals to take control of their pain management in a way traditional medications cannot.

David Veino, President and CEO of Neuros Medical, expresses pride in this first commercial implantation, highlighting its significance in addressing an unmet medical need. "We are proud to offer new hope to patients who have limited options for durable pain relief," he states. Meanwhile, the procedure was expertly conducted at Baylor Scott & White Heart and Vascular Hospital in Dallas, Texas, marking a critical milestone in the Altius System's journey to provide relief for many.

The Need for Innovative Solutions

There are over two million people in the United States living with limb loss. Each year, approximately 300,000 new lower limb amputations occur, often leading to severe lingering pain that interrupts daily life. Traditional pain relief methods have limitations, and many patients find themselves stuck in a cycle of dependency on pain medications, struggling to maintain a quality of life. This highlights the urgency for innovative solutions like the Altius System, which aims to tackle the underlying causes of pain rather than merely masking symptoms.

Neuros Medical's commitment goes beyond just product rollout; it’s a mission rooted in compassion and responsibility to help those living with chronic post-amputation pain. The company’s core values emphasize patient-first strategies and excellence in service, ensuring that every innovation is aimed at enhancing the lives of its users.

Future Directions

As the Altius System gains traction, its approval signifies a promising trend toward more patient-centric pain management technologies. This device not only fills the current gap in treatment but also sets the stage for further advancements in neuromodulation therapies. Neuros Medical is optimistic about expanding accessibility to these technologies and even exploring additional therapeutic applications in the future.

In conclusion, the introduction of the Altius® Direct Electrical Nerve Stimulation System heralds a new dawn for those afflicted by chronic post-amputation pain. As more institutions begin to adopt this technology, patients can look forward to a brighter future, free from the chains of pain and dependency, empowered by their ability to manage their health effectively. Neuros Medical stands at the forefront of this change, driven by a mission to relieve pain and restore life to those who need it most.